Related Experiment Videos
Solution structure of core binding factor beta and map of the CBF alpha binding site
1Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville 22906, USA.
Nature Structural Biology
|July 15, 1999
Summary
Core-binding factor beta (CBF beta) is crucial for development and its gene is linked to leukemia. Researchers determined the high-resolution structure of the CBF beta heterodimerization domain, revealing its novel alpha/beta fold and mapping the CBF alpha binding site.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Biology
Background:
- Core-binding factor beta (CBF beta) is essential for transcription factors involved in hematopoiesis and bone development.
- The human CBFB gene is frequently involved in chromosomal translocations associated with human leukemias.
- The N-terminal 141 amino acids of CBF beta contain the heterodimerization domain critical for binding CBF alpha subunits.
Purpose of the Study:
- To determine the high-resolution solution structure of the CBF beta heterodimerization domain.
- To elucidate the structural basis for the interaction between CBF beta and CBF alpha subunits.
- To map the CBF alpha binding site on CBF beta.
Main Methods:
- High-resolution solution structure determination of the CBF beta heterodimerization domain.
- Chemical shift perturbation analysis to map protein-protein interaction sites.
Main Results:
- The CBF beta heterodimerization domain adopts a novel alpha/beta structural fold.
- The structure consists of two anti-parallel three-stranded beta-sheets forming a sandwich, with four peripheral alpha-helices.
- The CBF alpha binding site on CBF beta was successfully mapped using chemical shift perturbation.
Conclusions:
- The determined structure provides critical insights into the molecular mechanisms of core-binding factor function.
- Understanding the CBF beta structure and its interaction with CBF alpha is vital for research into hematopoiesis and leukemia.
- This structural information can inform future therapeutic strategies targeting CBF beta in leukemia.